Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: Survey results from the members of the European Society of Gynecological Oncology

International Journal of Gynecological Cancer

Volumn 22, Issue 3, 2012, Pages 407-416

  Cornelis, Sarah ^a   Van Calster, Ben ^a,b   Amant, Frederic ^a   Leunen, Karin ^a   Van Der Zee, Ate Gerard Jan ^c   Vergote, Ignace ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Katholieke Universiteit   (Belgium)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Advanced ovarian cancer; European Society of Gynecological Oncology; Management; Survey

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; HEALTH SURVEY; HUMAN; LAPAROSCOPY; MEDICAL SOCIETY; MONOTHERAPY; OVARY CANCER; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; SELF REPORT;

CARCINOMA; DATA COLLECTION; EUROPE; FEMALE; GEOGRAPHY; GYNECOLOGY; HUMANS; MEDICAL ONCOLOGY; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIAN'S ROLE; QUESTIONNAIRES; SOCIETIES, MEDICAL;

EID: 84858205611     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31823ea1d8     Document Type: Article

References (28)

1. Verma M. Methods of Molecular Biology, Cancer Epidemiology. vol. 472. Totowa, NJ: Humana Press; 2009.
2. Verleye L, Ottevanger PB, van der Graaf W, et al. Gynaecological Cancer Group (GCG) of European Organisation for Research and Treatment of Cancer (EORTC). EORTC-GCG process quality indicators for ovarian cancer surgery. Eur J Cancer. 2009;45:517-526.
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.
4. Colombo N, Van Gorp T, Parma G, et al. Ovarian cancer. Crit Rev Oncol Hematol. 2006;60:159-179. (Pubitemid 44636248)
5. Martinek IE, Kehoe S. When should surgical cytoreduction in advanced ovarian cancer take place? J Oncol. 2010;2010:8520-8528.
6. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248-1259. (Pubitemid 34177431)
7. Covens A, Carey M, Bryson P, et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III or IV epithelial ovarian cancer. Gynecol Oncol. 2002;85:71-80.
8. Winter WE 3rd, Maxwell GL, Tian C, et al; Gynecologic Oncology Group Study. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621-3627. (Pubitemid 47372600)
9. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115:1234-1244.
10. Vergote I, van Gorp T, Amant F, et al. Timing of debulking surgery in advanced ovarian cancer. Int J Gynecol Cancer. 2008;18:11-19. (Pubitemid 351389047)
11. Verleye L, Ottevanger PB, Vergote I. Surgical program building in advanced ovarian cancer: European perspective. Gynecol Oncol. 2009;114:S10-S14.
12. Verleye L, Vergote I, van der Zee AG. Patterns of care in surgery for ovarian cancer in Europe. Eur J Surg Oncol. 2010;36: S108-S114.
13. Trope C, Kaern J. Primary surgery for ovarian cancer. Eur J Surg Oncol. 2006;32:844-852. (Pubitemid 44469295)
14. du Bois A, Rochon J, Pfisterer J, et al. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol. 2009;112:422-436. Epub 2008 Nov 6.
15. Vergote I, De Wever I, Tjalma W, et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol. 1998;71:431-436. (Pubitemid 29022333)
16. Inciura A, Simavicius A, Juozaityte E, et al. Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients. BMC Cancer. 2006;6:153.
17. Schwartz PE, Rutherford TJ, Chambers JT, et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol. 1999;72:93-99. (Pubitemid 29045454)
18. Morice P, Dubernard G, Rey A, et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg. 2003;197:955-963. (Pubitemid 38199555)
19. Sehouli J, Savvatis K, Braicu EI, et al. Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis. Int J Gynecol Cancer. 2010;20:1331-1340.
20. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006;103: 1070-1076. (Pubitemid 44821335)
21. Kang S, Nam BH. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol. 2009;16:2315-2320.
22. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953.
23. Dewdney SB, Rimel BJ, Reinhart AJ, et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynaecologic Oncologists. Gynecol Oncol. 2010;119:18-21.
24. Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS system. 2nd ed. Cary, NC: SAS Press; 2000.
25. Colombo PE, Mourregot A, Fabbro M, et al. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol. 2009;35:135-143.
26. Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with 'biological aggressiveness' and survival? Gynecol Oncol. 2001;82:435-441. (Pubitemid 32826441)
27. Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103:559-564. (Pubitemid 44602167)
28. Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21:750-755.